Overall, thiazolidinediones (TZDs), such as rosiglitazone (Avandia) and pioglitazone (Actos), raise heart-failure risk by 42%. Overall, dipeptidyl peptidase-4 (DPP-4) inhibitors, including saxagliptin and alogliptin, raise heart-failure risk by about 25%.

Good news: If you are overweight, losing weight to control blood sugar reduces the risk.

Want to Keep Reading?

Continue reading with a Health Confidential membership.

Sign up now Already have an account? Sign in